EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieLeserbriefOpen Access · CC BY 4.0

Venetoclax and hypomethylating agents versus tagraxofusp in older patients with blastic plasmacytoid dendritic cell neoplasm

Benjamin J Lee

Annals of Hematology · 2025-03 · 104 (3) · 2069-2071

DOI: 10.1007/s00277-025-06221-4 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, online erschienen am 20.02.2025. Verfasst von Benjamin J Lee. Beteiligte Einrichtung: Department of Pharmacy, Chao Family Comprehensive Cancer Center, University of California Irvine Health, 101 The City Drive South, Bldg. 23, Rm 275, …. Hauptthemen laut MEDLINE: Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Dendritic Cells, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive and rare hematologic malignancy characterized by poor response to multiagent chemotherapy and dismal survival outcomes of 8–16 months. Tagraxofusp, the first-in-class CD123-directed antineoplastic agent, has emerged as a highly effective therapy and is the only FDA approved drug for BPDCN. Nonetheless, significant treatment-related toxicities with tagraxofusp such as hepatotoxicity and capillary leak syndrome are unfortunately not uncommon and can be prohibitive for older or unfit patients. The success of venetoclax (VEN) with a hypomethylating agent (HMA) has recently been described in the literature however, clinical outcomes are limited to case reports and small case series. To confirm these findings, we performed a multicenter, retrospective cohort study utilizing the TriNetX Networks database to compare survival outcomes between BPDCN patients (≥60 years-of-age) who received VEN + HMA versus tagraxofusp. In total, 32 and 39 patients received VEN + HMA and tagraxofusp, respectively, between February 1, 2019 and September 1, 2024. Median follow-up time was 7.4 and 9.3 months in the VEN + HMA and tagraxofusp cohorts, respectively. Overall survival (OS) between VEN + HMA and tagraxofusp-treated patients was comparable at 12-months (41.2% vs. 53%; HR 1.15; 95% CI, 0.53–2.48; P = 0.73). In a subgroup analysis of older adult patients (≥75 years-of-age), OS at 12-months (38.1% vs. 56.5%; HR 1.20; 95% CI, 0.47–3.04; P = 0.71) was not significantly different. In conclusion, this large-scale, retrospective database analysis suggests that VEN + HMA is an effective therapeutic alternative to tagraxofusp in older patients for the management of BPDCN. Future studies are needed to prospectively validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulfonamidesBridged Bicyclo Compounds, HeterocyclicDendritic CellsAntineoplastic Combined Chemotherapy ProtocolsHematologic NeoplasmsRecombinant Fusion ProteinsHumansAgedMaleFemaleRetrospective StudiesMiddle AgedAged, 80 and overBlastic Plasmacytoid Dendritic Cell Neoplasm

Stichwörter der Autor:innen

BPDCNBlastic plasmacytoid dendritic cell neoplasmTagraxofuspVenetoclax

Substanzen

venetoclaxSulfonamidesBridged Bicyclo Compounds, HeterocyclictagraxofuspRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Pharmacy, Chao Family Comprehensive Cancer Center, University of California Irvine Health, 101 The City Drive South, Bldg. 23, Rm 275, Orange, CA, 92868, USA. benjaml9@hs.uci.edu.
  • Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, CA, USA. benjaml9@hs.uci.edu.

Zitieren

APA

Lee, B. J. (2025). Venetoclax and hypomethylating agents versus tagraxofusp in older patients with blastic plasmacytoid dendritic cell neoplasm. Annals of Hematology, 104(3), 2069-2071. https://doi.org/10.1007/s00277-025-06221-4

Vancouver

Lee BJ. Venetoclax and hypomethylating agents versus tagraxofusp in older patients with blastic plasmacytoid dendritic cell neoplasm. Annals of Hematology. 2025;104(3):2069-2071. doi:10.1007/s00277-025-06221-4

BibTeX
@article{Lee2025,
  author = {Lee, Benjamin J},
  title = {Venetoclax and hypomethylating agents versus tagraxofusp in older patients with blastic plasmacytoid dendritic cell neoplasm},
  journal = {Annals of Hematology},
  year = {2025},
  volume = {104},
  number = {3},
  pages = {2069--2071},
  doi = {10.1007/s00277-025-06221-4}
}
Kostenlos starten →